COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01426880
Recruitment Status : Completed
First Posted : September 1, 2011
Last Update Posted : February 15, 2016
Teva Pharmaceuticals USA
Roche Pharma AG
Information provided by (Responsible Party):
German Breast Group

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 2013
Actual Study Completion Date : August 2013
Publications of Results:

Publications automatically indexed to this study by Identifier (NCT Number):